Our rechallenge of cobimetinib in an Erdheim-Chester Disease (ECD) patient for the rare adverse effect, "dropped head syndrome," with a previously unexplored cobimetinib regimen was successful. Similar to other experiences with targeted agents in ECD, dosing of cobimetinib may vary to mitigate toxicity without impairing efficacy.
Keywords: Erdheim‐Chester disease; hematology; neurology; pharmacology.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.